Olr1748 inhibitors represent a class of chemical compounds that target the olfactory receptor OR1748, a G-protein-coupled receptor (GPCR) primarily involved in the detection of specific odorants. The Olr1748 receptor is part of a broader family of olfactory receptors that mediate the sense of smell through intricate signaling pathways. These inhibitors are designed to bind selectively to the OR1748 receptor, effectively blocking its interaction with natural ligands and disrupting the normal signal transduction processes. Structurally, Olr1748 inhibitors often contain specific moieties that enable high-affinity binding to the receptor's active site, preventing conformational changes necessary for receptor activation. This blockade at the molecular level can result in a significant reduction or complete inhibition of signal transmission through the olfactory pathway, providing a valuable tool for studying the mechanistic aspects of olfaction and receptor function.
Chemically, Olr1748 inhibitors may vary in their backbone structures, but they generally share common features such as lipophilic domains that interact with the hydrophobic regions of the receptor, as well as polar functional groups that engage in hydrogen bonding with key residues within the receptor's binding pocket. The design and synthesis of these inhibitors often involve sophisticated techniques like structure-based drug design (SBDD) and computational modeling to predict binding affinity and specificity. Additionally, the optimization of Olr1748 inhibitors requires a detailed understanding of the receptor's 3D structure, ligand-binding kinetics, and the physicochemical properties that govern receptor-ligand interactions. These inhibitors are invaluable for probing the functional dynamics of OR1748, offering insights into the structural biology of olfactory receptors and their role in sensory perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR tyrosine kinase inhibitor, potentially disrupting signaling pathways that could regulate Olr1748. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, might modulate MAPK/ERK signaling, influencing Olr1748 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, could affect pathways influencing Olr1748, like angiogenesis or cell proliferation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, might impact cell cycle regulation pathways affecting Olr1748. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, could affect protein degradation mechanisms relevant to Olr1748. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor, potentially disrupting signaling pathways regulating Olr1748. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL kinase inhibitor, might affect cell proliferation and survival pathways influencing Olr1748. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor, could alter cell proliferation and survival pathways affecting Olr1748. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor, potentially modulating signaling pathways relevant to Olr1748's function. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase inhibitor, might disrupt several signaling pathways involving Olr1748. | ||||||